The main purpose of this legislation is to streamline the approval process for certain drugs by allowing them to be approved even if their labeling lacks specific safety information, as long as that information is protected by exclusivity or patent rights. This aims to make safe generic drugs more readily available to the public. Key provisions of the legislation include a new rule that states a drug can still be approved even if it omits certain safety information from its labeling.